PartnershipApr 16, 2026, 06:01 AM
Aligos Secures $25M Upfront in $445M China HBV Deal
AI Summary
Aligos Therapeutics has entered an exclusive license agreement with Amoytop Biotech for pevifoscorvir sodium in Greater China, targeting chronic HBV infection. The deal includes an upfront payment of $25 million and up to $420 million in potential clinical, regulatory, and sales milestones, along with tiered high single-digit royalties. This partnership is expected to accelerate development in the region and extend Aligos's cash runway into the fourth quarter of 2026.
Key Highlights
- Received $25 million upfront payment.
- Eligible for up to $420 million in milestones.
- Tiered, high single-digit royalties on net sales.
- Extends cash runway into Q4 2026.
- Amoytop to fund development in Greater China.